Jon Jones’ Post

🎓PhunD x Jon Chee Chat: Thrilled to finally meet Jon Chee, CEO of Excedr—a laboratory support program that provides researchers with cutting-edge instrument leases and comprehensive coverage plans tied to the goal of saving researchers time and money, offering a smarter way to do research. We both share a hug-friendly ethos, making our meetup warm and genuine! We discussed: • Our mutual journey in academia, Jon's starting at University of California, Berkeley's Bjeldanes Lab and Leitman Lab, and my background at the University of Washington - School of Medicine. • The wonderful rollercoaster ride that Excedr has been on since its inception in 2011. • Jon's critical feedback on PhunD, ranging from prioritization to potential monetization strategies. • Our mutual ethos to uplift academia and Jon's passionate belief in PhunD's potential. • The invaluable nuggets Jon shared about bootstrapping, VC funding, and the practicalities of running a scalable scholarship program. • Introductions that Jon generously offered to make on my behalf. We were charged with excitement, innovation, and mutual respect for each other's visions. 🙏 See what the hubbub is about 👇 PhunD Waitlist: https://lnkd.in/gqPfiX_p Survey for Scholars: https://lnkd.in/ga4hhEYP Y Combinator Pitch: https://lnkd.in/g2HsArzd Get exclusive access to Discuss It: https://lnkd.in/gAtxfAYt --- 📌 About Jon Chee: Jon is more than just the CEO and co-founder of Excedr; he is a comrade in the journey to transform academic funding. Raised in Berkeley, the son of a structural engineer father and a mortgage broker mother, Jon has academic roots at University of California, Berkeley, where he delved deep in undergraduate research. He was mentored in the Bjeldanes Lab and Leitman Lab, finishing a degree in Molecular Toxicology. Jon also launched "The Biotech Startups Podcast," which has quickly gained traction with over 20,000 monthly listeners. You should absolutely check it out: https://lnkd.in/g8XadEdz His firm, Excedr, aims to eliminate financial barriers in academic labs, a mission echoing his own personal ethos to pay it forward. Jon sees PhunD as a potential channel for his company to distribute scalable scholarships. His support extends beyond our professional dialogue; he's made himself available for any guidance I may need, solidifying our bond of comradeship. #PhunD #Excedr #academia #phd #postdoc #innovation #financialsolutions

2023 was a brilliant year for AIDD. This article explores some of the things we can expect in the year ahead. 1. Further consolidation of the AIDD space 2. A new wave of startups and investment 3. Transition from platform partnerships to asset/software licensing 4. NVIDIA will play a major role in AIDD Software 5. Isomorphic Labs will announce multiple big pharma deals What else do you think we can expect over the next year? The point about the work of NVIDIA is something I posted about earlier this week. They have, and will continue to, impact the AIDD space more significantly than any other player. I will be keeping my LinkedIn up to date with important AIDD news as it unfolds in 2024, follow for more! #drugdiscovery #aidd #artificialintelligence

Congratulations to the following Lightspeed-backed companies on their recent funding announcements: → Wiz, a Cloud Security Platform helping hundreds of the world's leading and fastest-growing organizations rapidly identify and remove critical risks in cloud environments. cc: Co-Founders Yinon C., Assaf Rappaport, Ami Luttwak, and Roy Reznik. → Suno, a generative artificial intelligence music creation program building a future where anyone can make great music. cc: Co-Founders Mikey Shulman Georg Kucsko, Martin Camacho, and Keenan Freyberg → Pheon Therapeutics, a leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. cc: President & CEO Cyrus Mozayeni and Co-Founder Paul Jackson → Patronus AI, the first automated evaluation and security platform that helps companies detect large language model (LLM) mistakes at scale. cc: Co-Founders Anand Kannappan and Rebecca Qian Swipe to find out more about their missions and visions.

Elon's brain chip startup! Is this exciting or absolutely terrifying? 🤯 We are closing the gap faster and faster to a Black Mirror reality with the pace of technological development today. I'm curious to see Neuralink's results of the first-in-human clinical trial.

🌟 Top 3 Highlights from May on LinkedIn! 🌟 These three posts were the most viewed on our feed this month! - SOPHiA GENETICS, Microsoft, and NVIDIA Partnership 🚀 - Automata Technologies Secures $40M Funding 💸 - Watchmaker Genomics and SPT Labtech Collaboration 🔬 Honorable Mention: - Radar Therapeutics Raises $13.4M in Seed Financing 💉 🚀 SOPHiA GENETICS, Microsoft, and NVIDIA Partnership 🚀 SOPHiA GENETICS is collaborating with Microsoft and NVIDIA to revolutionize whole genome sequencing (WGS). This innovative WGS analytical solution will leverage Microsoft Azure's scalable infrastructure and NVIDIA Parabricks' powerful genomics analysis software. 💸 Automata Technologies Secures $40M Funding 💸 London-based biotech firm Automata Technologies has raised $40M to advance its robotic automation solutions for life sciences labs. The funding, led by Dimension and A.P. Moller Holding, will fuel expansion across Europe, the UK, and the US. 🔬 Watchmaker Genomics and SPT Labtech Collaboration 🔬 Watchmaker Genomics and SPT Labtech have partnered to automate library preparation for next-generation sequencing (NGS). Their integrated solution enhances efficiency and accessibility in genomic sequencing, paving the way for advancements in genetic research and diagnostics. 💉 Honorable Mention: Radar Therapeutics Raises $13.4M in Seed Financing 💉 Radar Therapeutics has successfully raised $13.4M in seed financing to develop smart programmable medicines using molecular RNA sensors. The funding round was led by NfX Bio with participation from major investors including Eli Lilly and Company, Biovision Ventures, and KdT Ventures. What a month for innovation and advancements in genomics and biotech! Let's keep the momentum going! link of the different posts in the comments🚀🔬🌐

Via Scientific, Inc., the pioneering informatics startup, proudly announced securing $5 million in seed funding on Tuesday. Spearheaded by G20 Ventures and Innospark Ventures, the financing round also saw contributions from prominent figures like Melissa Moore, a founding scientist and former CSO of Moderna, Rob Hickey, ex-executive VP of DataRobot, and Via Scientific's own Janet Kosloff, previously the CEO of InCrowd. At its core, Via Scientific is propelling a cutting-edge multiomics platform, initially conceived at the University of Massachusetts Chan Medical School. This platform leverages AI to scrutinize vast biological datasets, unveiling groundbreaking associations between biological components, pinpointing pivotal biomarkers and pathways, and uncovering markers indicative of diseases and physiological factors. The infusion of seed funding marks a pivotal moment for Via Scientific. The capital injection will fuel the company's commercialization initiatives, facilitating the expansion of its repository of bioinformatic processes, pipelines, and AI models. Moreover, it will support the augmentation of its technology and scientific teams, fortifying the company's presence and impact in Boston and beyond. #multiomics #ai #bioinformatics #seedfunding #innovationinscience

Tomorrow 7.30-10am PT (online), for accredited investors! R42 AI and Longevity Investors Network Nov 1 Meeting The R42 AI and Longevity Investors Network, brings together investors and promising early-stage AI/Deep Tech and Longevity Biotech startups. The companies presenting are a mix of R42 Group portfolio companies and new companies. Will have up to 5 companies pitching, followed by due diligence meetings with a smaller group of interested investors and companies being evaluated. Ronjon Nag

Neuralink What do you think about #Neuralink. Implementation of chips in the human brain to cure diseases, for example. Which team are you? A) Love it! 😍  B) I do not know yet? 🤔  C) No way! 💩 #Transformation #Startup #Technology